In Invitrogen’s first-quarter conference call, company executives said the company’s RNAi business, which comes from its November 2003 acquisition of Sequitur, is growing.

Although revenue growth was flat for the company’s core genomics business, “our RNAi business is going very strong,” CEO and President Greg Lucier said in the call Thursday. “We are really pleased with the overall Stealth RNAi business and that’s right on track in terms of its performance.”